[Helicobacter pylori infection and probiotics].
Kamiya
Shigeru
S
Department of Infectious Diseases, Kyorin University School of Medicine.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000658:Amoxicillin / Q000627:therapeutic use; D000818:Animals; D001644:Bifidobacterium; D017291:Clarithromycin / Q000627:therapeutic use; D046972:Clostridium butyricum; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000382:microbiology / Q000517:prevention & control* / Q000628:therapy*; D016480:Helicobacter pylori; D006801:Humans; D007778:Lactobacillus; D064747:Lansoprazole; D019936:Probiotics / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012440:Saccharomyces
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin